Dr. Degong Mu, one of the co-corresponding authors of the article entitled, “Screening of Clinical Factors Related to Prognosis of Breast Cancer Based on the Cox Proportional Risk Model,” (by Wan Tang, Degong Mu, Ling Han, Xianmin Guo, Bing Han, and Dong Song; J Comput Biol. 2021;28(1):89–98; doi: 10.1089/cmb.2019.0110) has requested a full retraction of the published paper based on the following reasons:
We could not prove that the clinical characteristics listed in Table 1 were independent prognostic factors using a
p value <0.05. Further, we could not prove that patients with younger age and lower stage showed better overall clinical survival according to the column map in Figure 2. We thus cannot ensure the reliability of our conclusions, and we have to retract the article. We apologize to the editors and readers of the journal. [sic]
The Publisher secured all coauthors' agreements to officially retract the article.
Get full access to this article
View all access options for this article.
References
1.
AndersonW.I., SchlaferD.H., and VeselyK.R.1989. Thyroid follicular carcinoma with pulmonary metastases in a beaver (Castor canadensis). J. Wildl. Dis. 25, 599–600.
2.
ArteagaC.L., SliwkowskiM.X., OsborneC.K., et al.2011. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol. 9, 16.
3.
BeseN.S., KielK., BelkE.Get al.2010. Radiotherapy for breast cancer in countries with limited resources: Program implementation and evidence-based recommendations. Breast J. 12, S96–S102.
4.
BuddeM.D., GoldE., JordanE.K., et al.2012. Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. Clin. Exp. Metastas. 29, 51–62.
5.
CameronD., PiccartgebhartM.J., GelberR.D., et al.2017. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, 389, 1195–1205.
6.
DrPHD.B.T.M. 1984. Do hormones cause breast cancer?. Cancer, 53, 595–604.
7.
EfirdJ.T., HunterS., ChanS., et al.2018. The association between age, comorbidities and use of radiotherapy in women with breast cancer: Implications for survival. Medicines (Basel), 5, 62.
8.
ElstonC.W., and EllisI.O.2010. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology, 19, 403–410.
9.
EngK.H., SchillerE., and MorrellK.2015. On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. Oncotarget, 6, 36308–36318.
10.
GilewskiT., RagupathiG., BhutaS., et al.2001. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial. Proc. Natl. Acad. Sci. U. S. A. 98, 3270–3275.
11.
GonzalezA.B.D., CurtisR.E., GilbertE., et al.2010. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br. J. Cancer, 102, 220–226.
12.
HarariD., and YardenY.2000. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene, 19, 6102.
13.
HickeyB.E., FrancisD.P., and LehmanM.2013. Sequencing of chemotherapy and radiotherapy for early breast cancer. Cochrane Database Syst. Rev. 4, CD005212.
14.
HigaG.M., and FellR.G.2013. Sex hormone receptor repertoire in breast cancer. Int. J. Breast Cancer, 2013:284036.
15.
JPOGN.c.p.b.f.b.c. 2014. Neoadjuvant chemotherapy plus bevacizumab for breast cancer. Lancet Oncol. 15, 131–132.
16.
LacnyS., WilsonT., ClementF., et al.2015. Kaplan-Meier survival analysis overestimates the risk of revision arthroplasty: A meta-analysis. Clin. Orthop. Relat. Res. 473, 3431–3442.
17.
LongeneckerB.M., ReddishM., KogantyR., et al.2010. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann. NY Acad. Sci. 690, 276–291.
18.
LuL.J.W., AndersonK.E., GradyJ.J., et al.2000. Decreased ovarian hormones during a soya diet: Implications for breast cancer prevention. Cancer Res. 60, 4112–4121.
19.
MilioliH.H., VimieiroR., RiverosC., et al.2015. The discovery of novel biomarkers improves breast cancer intrinsic subtype prediction and reconciles the labels in the METABRIC data set. PLoS One, 10, e0129711.
20.
MüllerA., HomeyB., SotoH., et al.2001. Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50–56.
21.
NathansonK.N., WoosterR., and WeberB.L.2001. Breast cancer genetics: What we know and what we need. Nat Med. 7, 552–556.
22.
Piccart-GebhartM. J., ProcterM., Leyland-JonesB., et al.2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659.
23.
RechtA., SilenW., SchnittS.J., et al.1988. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 15, 255–261.
24.
SestakI., BuusR., CuzickJ., et al.2018. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol, 4:545–553.
25.
ShaoT., GrossbardM.L., and KleinP.2011. Breast cancer in female-to-male transsexuals: Two cases with a review of physiology and management. Clin Breast Cancer, 11, 417–419.
26.
SmithI., ProcterM., GelberR.D., et al.2007. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet, 369, 29–36.
27.
VeronesiU., BoyleP., GoldhirschA., et al.2005. Breast cancer. Lancet, 365, 1727–1741.
28.
VonM. G., EidtmannH., RezaiM., et al.2012. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. New Engl J Med, 366, 299.
29.
WangP., WangY., HangB., et al.2016. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget, 7, 55343–55351.
30.
YardenY.2001. Biology of HER2 and its importance in breast cancer. Oncology, 61, 1–13.
